MORTALITY PREDICTORS IN PATIENTS REFERRED FOR BUT NOT UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT  by Kang, Donna et al.
Valvular Heart Disease
A2036
JACC March 17, 2015
Volume 65, Issue 10S
mortAlity PreDictors in PAtients referreD for But not unDergoing trAnscAtheter 
Aortic vAlve rePlAcement
Poster Contributions
Poster Hall B1
Monday, March 16, 2015, 9:45 a.m.-10:30 a.m.
Session Title: Prosthetic Valve Disease
Abstract Category: 40.  Valvular Heart Disease: Clinical
Presentation Number: 1262-354
Authors: Donna Kang, David Bach, Stanley Chetcuti, George M. Deeb, Paul Grossman, Himanshu Patel, Daniel Menees, Matthew 
Romano, Troy LaBounty, University of Michigan Health System, Ann Arbor, MI, USA
Background:  Transcatheter aortic valve replacement (TAVR) has expanded the proportion of patients with aortic stenosis (AS) who 
are candidates for valve replacement. Nevertheless, many patients remain untreated, and their prognosis and mortality risk factors are 
incompletely understood.
methods:  We evaluated 172 consecutive patients with severe AS referred for TAVR who declined (n=55) or were not candidates for 
(n=117) intervention. We evaluated all-cause mortality, and examined clinical and echocardiographic variables associated with mortality.
results:  There were 77 deaths, and mean follow-up was 17.9±10.9 months for survivors. Mortality at 1 and 2 years was 39.2% and 
52.6%, respectively. There was a difference in mortality between patients who declined the procedure and those who were not candidates, 
with 1-year mortality rates of 20.6% and 48.4%, respectively (p=0.001). On multivariable analysis, four variables were independently 
associated with mortality: New York Heart Association Class IV heart failure (hazard ratio [HR] 2.6, 95% confidence interval [CI] 1.6-4.2, 
p<0.001), glomerular filtration rate <48 mL/min (HR 2.1, 95% CI 1.3-3.4, p=0.002), albumin <3.9 g/dL (HR 1.9, 95% CI 1.2-3.1, p=0.007), 
and ejection fraction <50% (HR 1.9, 95% CI 1.4-3.0, p=0.01). The number of baseline variables was associated with one-year mortality 
rates of 24.4%, 22.3%, 46.1%, 79.8%, and 90.0% for 0-4 variables, respectively (p<0.001, area under curve 0.72).
conclusion:  Patients with severe symptomatic AS who remain untreated after referral for TAVR experience a mortality rate of 41% at one 
year. Independent predictors of mortality include advanced heart failure, renal dysfunction, low albumin, and left ventricular dysfunction. 
The presence of more than one of these variables can identify patients at markedly increased risk of mortality.
